BRAF and colorectal carcinoma: For example, BRAFi (PLX4032 or vermurafenib) induces a rapid, marked feedback activation of EGFR in the BRAF (V600E)-mutated CRC cell lines, supporting continued proliferation in the presence of BRAF inhibition [9, 11].